Stopping Ozempic-Like Drugs Raises Heart Attack, Stroke and Death Risk 22% After 2 Years
Updated
Updated · ScienceDaily · Sep 21
Stopping Ozempic-Like Drugs Raises Heart Attack, Stroke and Death Risk 22% After 2 Years
3 articles · Updated · ScienceDaily · Sep 21
Summary
A BMJ Medicine study of 333,687 U.S. veterans with type 2 diabetes found GLP-1 users who stopped treatment for two years faced a 22% higher risk of heart attack, stroke and death than those who stayed on it.
Even a six-month interruption weakened protection, and the longer patients stayed off Ozempic-, Wegovy-, Mounjaro- or Zepbound-type drugs, the more cardiovascular benefit they lost.
Continuous use delivered the strongest effect: patients who stayed on GLP-1 therapy for three years had an 18% lower risk of major cardiovascular events than those taking sulfonylureas—about four fewer events per 100 people.
Restarting after a gap restored only part of the benefit, with temporary stoppages linked to a 4% to 8% higher cardiovascular risk than uninterrupted treatment.
About 1 in 8 U.S. adults now use GLP-1 drugs, and the researchers said cost, side effects and shortages often drive discontinuation despite the drugs' heart-protection benefits.
If GLP-1 heart benefits vanish after stopping, are we treating cardiovascular disease or just renting a temporary, expensive cure?
Could quitting your popular weight-loss shot trigger a metabolic whiplash that leaves your heart in more danger than before you started?
Stopping GLP-1 Drugs Raises Heart Attack and Stroke Risk by Up to 22%: The Urgent Need for Continuous Therapy and Policy Reform
Overview
This report reveals that stopping GLP-1 medications like semaglutide or tirzepatide leads to a rapid and dangerous surge in cardiovascular risk, erasing years of heart protection and causing direct damage to the cardiovascular system through a process called 'metabolic whiplash.' While continuous use of GLP-1s can reduce major heart events by 18%, even a year off the drugs increases risk by 14%, and two years off wipes out nearly all benefits. High costs, insurance barriers, and side effects cause up to 65% of patients to discontinue treatment in the first year. Alternatives like oral orforglipron and endoscopic procedures can help maintain weight loss, while new policies and generics aim to improve access and affordability.